Non-adherence is a shared issue, impacting all healthcare stakeholders. Patients will not gain the full benefit of their treatment, which may increase the need for medical intervention and even death. The healthcare system experiences inefficient use of resources and increased ong-term costs. The biopharma industry’s innovative products are not used effectively, leading to lower real-world efficacy and diminished perceptions of product value.